

Statin adherence and persistence on secondary prevention of cardiovascular disease in Taiwan**Supplementary: Characteristics of ASCVD hospital discharge patients and patients initiated a statin within 90-day of their discharge**

Variable	initiated a statin		not initiated statin		total New-onset ASCVD	
Number of events	185,252	100%	318,895	100%	504,147	100%
Age [mean, SD]	[65.4, 12.0]				[68.7 (12.8)]	
Male	122,881	66%	201,550	63%	324,431	64%
Female	62,371	34%	117,345	37%	179,716	36%
Statin use during hospitalization	151,020	82%	33,717	11%	184,737	37%
Previous use of statins	87,191	47%	46,298	15%	133,489	26%
Diagnosis of ASCVD events						
Ischemic stroke	74,753	40%	200,320	63%	275,073	55%
Acute myocardial infarction w/o PTCA/CABG	9,699	5%	32,484	10%	42,183	8%
Acute myocardial infarction with PTCA/CABG	33,021	18%	25,744	8%	58,765	12%
Stable CHD receiving revascularization	67,779	37%	60,347	19%	128,126	25%
Examinations during hospitalization						
Lipid exam	163,329	88%	251,872	79%	415,201	82%
EKG exam	146,867	79%	228,737	72%	375,604	75%
Examinations 1 year before ASCVD						
Lipid exam						
Number [mean, SD]	[1.59, 1.78]				[1.31 (1.68)]	
0 time	65,378	35%	151,572	48%	216,950	43%
1 time	40,545	22%	74,870	23%	115,415	23%
≥ 2 times	79,329	43%	92,453	29%	171,782	34%
EKG exam						
Number [mean, SD]	[1.23, 1.72]				[1.33 (1.85)]	
0 time	75,807	41%	127,280	40%	203,087	40%
1 time	54,008	29%	87,375	27%	141,383	28%
≥ 2 times	55,437	30%	104,240	33%	159,677	32%
One year before ASCVD						
Comorbidities						
Hypertension	126,530	68%	24,307	8%	150,837	30%
Ischemic heart disease	87,031	47%	113,128	35%	200,159	40%

Hyperlipidemia	81,655	44%	263,997	83%	345,652	69%
Diabetes	76,390	41%	119,956	38%	196,346	39%
COPD	18,112	10%	23,985	8%	42,097	8%
Renal failure	15,988	9%	35,822	11%	51,810	10%
Liver failure	14,004	8%	52,415	16%	66,419	13%
Cancer	8,877	5%	23,869	7%	32,746	6%
Depression	8,658	5%	20,522	6%	29,180	6%
Transient ischemic attack	7,512	4%	16,303	5%	23,815	5%
Dementia	4,702	3%	22,104	7%	26,806	5%
Charlson's comorbidity score [mean, SD]	[1.79, 1.81]				[2.17 (2.06)]	
Medications						
Antiplatelet agents	119,947	65%	177,558	56%	297,505	59%
CCBs	104,848	57%	184,030	58%	288,878	57%
β-blockers	92,994	50%	138,089	43%	231,083	46%
ARBs	72,550	39%	111,208	35%	183,758	36%
OADs	68,073	37%	102,016	32%	170,089	34%
Diuretics	56,981	31%	119,584	37%	176,565	35%
ACEIs	45,236	24%	79,385	25%	124,621	25%
Insulin	23,958	13%	42,739	13%	66,697	13%
Anticoagulants	18,080	10%	31,438	10%	49,518	10%
Digitalis	7,514	4%	24,867	8%	32,381	6%
At index statin prescription						
Healthcare organization accreditation level						
Medical center	95,326	51%	137,247	43%	232,573	46%
Regional hospital	58,111	31%	116,544	37%	174,655	35%
District hospital	17,129	9%	52,649	17%	69,778	14%
Other hospital	10,440	6%	16,701	5%	27,141	5%
Geographic location						
Taipei region	62,979	34%	94,307	30%	157,286	31%
Northern region	22,723	12%	44,378	14%	67,101	13%
Central region	32,740	18%	63,271	20%	96,011	19%
Southern region	30,274	16%	56,708	18%	86,982	17%
Kao-Ping region	30,730	17%	50,980	16%	81,710	16%
Eastern region	5,806	3%	9,251	3%	15,057	3%

Physician Specialty

Cardiovascular medicine	96,018	52%	102,892	32%	198,910	39%
Cardiovascular surgery	7,540	4%	13,170	4%	20,710	4%
Neurology	53,050	29%	140,592	44%	193,642	38%
Internal medicine (including endocrinology)	21,697	12%	39,494	12%	61,191	12%
Family medicine	2,971	2%	216	0%	3,187	1%
Others	3,976	2%	22,531	7%	26,507	5%
